Dexcom (NSDQ:DXCM) announced today that it signed a five-year collaboration agreement with the University of Virginia for CGM research. The partnership will focus on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous glucose monitoring (CGM) tools outside the Type 1 diabetes market, which includes inpatient hospital use, Type 2 diabetes and gestational […]
MedTech 100 roundup: Industry hits another mid-pandemic high
Despite a minor regression week-over-week, the medtech industry’s stocks hit another milestone as the COVID-19 rebound remains in progress. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.01 points at the end of last week (July 31). Overall, medtech stocks saw a -0.3% increase from the […]
The top 5 MassDevice stories of the week — July 31, 2020
The past week has seen a slew of Q2 earnings reports from medical device companies — and the picture overall hasn’t been pretty amid the COVID-19 pandemic. Still, medtech CEOs during their earnings calls said they’re starting to see some signs of hospital procedures recovering a bit even as the southern U.S. deals with a […]
Dexcom up after hours on Street-beating Q2
Dexcom (NSDQ:DXCM) shares ticked up after hours today on second-quarter results that blew away the consensus forecast. The San Diego-based continuous glucose monitoring technology developer posted profits of $46.3 million, or 48¢ per share, on sales of $451.8 million for the three months ended June 30, 2020, for a massive bottom-line gain after losses of $10.5 […]
DeviceTalks Weekly: Stryker CEO Kevin Lobo says medtech can increase workforce diversity
This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company — and the industry group AdvaMed that he currently leads — has been working to increase diversity of its workforce, particularly in […]
Dexcom CEO sees a new market for continuous glucose monitors after COVID-19
Could in-hospital use of continuous glucose monitors become a new normal after the COVID-19 pandemic? Dexcom CEO Kevin Sayer thinks so. As the pandemic ramped up in March, FDA issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance included CGMs made by companies such […]
Abbott FreeStyle Libre 2 iCGM FDA cleared for use in adults and children
Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 system for adults and children ages four and older with diabetes. The Abbott Park, Ill.-based company touts its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system as the only such system with optional real-time alarms that measure glucose levels every minute […]
Dexcom lands CE Mark for G6 glucose monitor
Dexcom (NSDQ:DXCM) announced today that it received CE Mark approval in Europe for its G6 continuous glucose monitoring system. The Dexcom G6 uses a small, wearable sensor and transmitter, now indicated to be placed on the back of the upper arm, to continuously measure and send glucose levels wirelessly to a dedicated receiver or compatible smart […]
Dexcom completes sale of $1.05B in notes
Dexcom (NSDQ:DXCM) announced that it completed the sale of $1.05 billion aggregate principal amount of its convertible senior notes. The San Diego-based continuous glucose monitoring system developer announced earlier this week that it was offering $850 million in notes with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate […]
DexCom prices $1.05B ‘upsized’ offering
Continuous glucose monitoring system developer Dexcom (NSDQ:DXCM) announced today that it priced an upsized offering worth $1.05 billion in convertible senior notes. Yesterday, the San Diego-based company announced an offering worth $850 million with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Today, […]
Dexcom to raise $850m from senior notes offering
Dexcom (NSDQ:DXCM) said today that it plans to offer an $850 million aggregate principal amount of convertible senior notes due 2025. The San Diego-based continuous glucose monitoring systems company also plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Dexcom plans to use $600 […]
- 1
- 2
- 3
- …
- 15
- Next Page »
